Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741480 | 0.80 | MAOB (0.81) | MAOBCYP4F2CYP4A11CYP3A4RAB9A | |
| SCHEMBL18664184 | 0.80 | MAOB (0.81) | MAOBCYP4F2CYP4A11CYP3A4RAB9A | |
| SCHEMBL11244637 | 0.80 | MAOB (0.54) | MAOBRAB9AMAOA | |
| SCHEMBL19962768 | 0.80 | MAOB (0.68) | MAOBCYP4F2CYP4A11RAB9AHRH3 | |
| SCHEMBL15038105 | 0.80 | MAOB (0.68) | MAOBCYP4F2CYP4A11RAB9AHRH3 | |
| SCHEMBL12854780 | 0.80 | APP (0.52) | MAOBRAB9AMAOA | |
| SCHEMBL15584627 | 0.78 | CYP19A1 (0.56) | MAOBRAB9ACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10925694 | 0.76 | MAOB (0.68) | MAOBCYP4F2CYP4A11CYP3A4RAB9A | |
| SCHEMBL16841039 | 0.75 | MAOB (0.72) | MAOBCYP4F2CYP4A11CYP3A4RAB9A | |
| SCHEMBL23541337 | 0.75 | MAOB (0.71) | MAOBCYP4F2CYP4A11CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556143-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9221791-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-04-09 | — | — | US | disclosed |
| US-8901121-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2014-11-27 | — | — | US | disclosed |
| US-8809378-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012177603-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177608-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAOB 246/4885CYP4F2 261/4885CYP4A11 966/4885 |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAOB 246/4885CYP4F2 261/4885CYP4A11 966/4885 |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAOB 246/4885CYP4F2 261/4885CYP4A11 966/4885 |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAOB 246/4885CYP4F2 261/4885CYP4A11 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.